Contract research organisation (CRO) Clearstone Central Laboratories has unveiled a ‘preferred provider’ partnership with Mitsubishi Chemical Medience (MCM), continuing its efforts to expand in Asia.
Clearstone Central Laboratories is to wind down or sell its centralised cardiac services (CCS) business because significant investment would be required to remain competitive.
Clearstone is expanding safety and esoteric capacity at its laboratory in Toronto, Canada, allowing it to close its facility in New Jersey, US and consolidate North American operations.
Latin America, new services and mid-sized pharma clients are targets for the incoming CEO of Clearstone Central Laboratories, who set out his vision for the business in an interview with Outsourcing-Pharma.
MDS’ Central Labs has been rebranded as Clearstone Central Laboratories following its acquisition by Czura Thornton, which is looking to expand the business and that of Chiltern, a CRO also owned by the investment company, into new geographies, according...
